Landscapes / Companies
UCB Biopharma SRL not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
4 approved
2 in Phase 3
Drugs
9
in active trials · 26 in all
Trials
27 active
123 since 2021
Drugs9
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | 21 Dec 2026Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 21 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis and 5 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 6 May 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 6 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Ocular Myasthenia Gravis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) and 2 more | ||||
| Open drug page | |||||
Complement inhibitor |
Approved | 12 May 2027Phase 2/3 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 12 May 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis | ||||
| Open drug page | |||||
— |
Approved | 16 Nov 2029Phase 3 trial completes | |||
| Next date | 16 Nov 2029 · Phase 3 trial completes | ||||
| Also tested for | Epilepsy, Childhood Absence Epilepsy and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | 29 Mar 2027Phase 3 trial completes | |||
| Next date | 29 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Stereotypical Prolonged Seizures | ||||
| Open drug page | |||||
Dapirolizumab pegolnot checked |
Monoclonal antibody |
Phase 3 | 31 May 2028Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 31 May 2028 · Phase 3 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 2 | 17 May 2027Phase 2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 17 May 2027 · Phase 2 trial completes | ||||
| Also tested for | Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | 13 Dec 2026soonPhase 1 trial completes | |||
| Next date | 13 Dec 2026 · Phase 1 trial completes | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 1 | 13 Dec 2027Phase 1 trial completes | |||
| How it works | An antibody | ||||
| Next date | 13 Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Progressive Supranuclear Palsy | ||||
| Open drug page | |||||
About
- No active trial
- 17 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021